[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. [2] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 磁共振成像, 2024, 15(6):1-18. [3] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314. [4] SINGAL A G, LAMPERTICO P, NAHON P. Epidemiology and surveillance for hepatocellular carcinoma:new trends[J]. J Hepatol, 2020, 72(2):250-261. [5] WANG W Y, WEI C. Advances in the early diagnosis of hepatocellular carcinoma[J]. Genes Dis, 2020, 7(3):308-319. [6] 戴靖宜, 蒋敬庭. 肝细胞肝癌肿瘤标志物诊断的新进展[J]. 诊断学理论与实践, 2023, 22(5):486-493. [7] QI Y F, XU R. Roles of PLODs in collagen synthesis and cancer progression[J]. Front Cell Dev Biol, 2018, 6:66. [8] SU H, KARIN M. Collagen architecture and signaling orchestrate cancer development[J]. Trends Cancer, 2023, 9(9):764-773. [9] SHAO Y K, XU K L, ZHENG X, et al. Proteomics profiling of colorectal cancer progression identifies PLOD2 as a potential therapeutic target[J]. Cancer Commun, 2022, 42(2):164-169. [10] LEWIS D M, PRUITT H, JAIN N, et al. A feedback loop between hypoxia and matrix stress relaxation increases oxygen-axis migration and metastasis in sarcoma[J]. Cancer Res, 2019, 79(8):1981-1995. [11] DU H Z, CHEN Y L, HOU X Y, et al. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC[J]. Cell Death Dis, 2017, 8(10):e3143. [12] MIYAMOTO K, SEKI N, MATSUSHITA R, et al. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer[J]. Br J Cancer, 2016, 115(3):354-363. [13] XU F F, ZHANG J L, HU G L, et al. Hypoxia and TGF-β1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation[J]. Cancer Cell Int, 2017, 17:54. [14] LI Y Z, PORTA-PARDO E, TOKHEIM C, et al. Pan-cancer proteogenomics connects oncogenic drivers to functional states[J]. Cell, 2023, 186(18):3921-3944. [15] LIAO C Q, WANG X. TCGAplot:an R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data[J]. BMC Bioinformatics, 2023, 24(1):483. [16] YU G C, WANG L G, HAN Y Y, et al. clusterProfiler:an R package for comparing biological themes among gene clusters[J]. OMICS, 2012, 16(5):284-287. [17] H-NZELMANN S, CASTELO R, GUINNEY J. GSVA gene set variation analysis for microarray and RNA-seq data[J]. BMC Bioinformatics, 2013, 14:7. [18] TAN D J H, NG C H, LIN S Y, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma:a systematic review and meta-analysis[J]. Lancet Oncol, 2022, 23(4):521-530. [19] WANG Z, FAN G T, ZHU H, et al. PLOD2 high expression associates with immune infiltration and facilitates cancer progression in osteosarcoma[J]. Front Oncol, 2022, 12:980390. [20] LEI X, LEI Y, LI J K, et al. Immune cells within the tumor microenvironment:biological functions and roles in cancer immunotherapy[J]. Cancer Lett, 2020, 470:126-133. [21] PE-A-ROMERO A C, ORENES-PI-ERO E. Dual effect of immune cells within tumour microenvironment:pro- and anti-tumour effects and their triggers[J]. Cancers, 2022, 14(7):1681. [22] SU H, JIN Y Q, TAO C Y, et al. Th2 cells infiltrating high-grade serous ovarian cancer:a feature that may account for the poor prognosis[J]. J Gynecol Oncol, 2023, 34(4):e48. [23] BUDHU A, WANG X W. The role of cytokines in hepatocellular carcinoma[J]. J Leukoc Biol, 2006, 80(6):1197-1213. [24] MA H Y, YAMAMOTO G, XU J, et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease[J]. J Hepatol, 2020, 72(5):946-959. [25] PENG C, YE Z, JU Y, et al. Mechanism of action and treatment of type I interferon in hepatocellular carcinoma[J]. Clin Transl Oncol, 2024, 26(2):326-337. [26] REIZIS B. Plasmacytoid dendritic cells:development, regulation, and function[J]. Immunity, 2019, 50(1):37-50. |